{"id":37337,"date":"2026-01-30T12:01:24","date_gmt":"2026-01-30T11:01:24","guid":{"rendered":"https:\/\/mabdesign.fr\/?p=37337"},"modified":"2026-01-30T12:04:32","modified_gmt":"2026-01-30T11:04:32","slug":"a-clinical-stage-biotechnology-company-and-a-leader-in-the-development-of-microbiome-ecosystem-therapiestm-met-dedicated-to-enhancing-survival-for-patients-with-cancer-through-immune-modulation","status":"publish","type":"post","link":"https:\/\/mabdesign.fr\/en\/a-clinical-stage-biotechnology-company-and-a-leader-in-the-development-of-microbiome-ecosystem-therapiestm-met-dedicated-to-enhancing-survival-for-patients-with-cancer-through-immune-modulation\/","title":{"rendered":"MaaT Pharma Announces First Patient Randomized in IMMUNOLIFE Phase 2 Study Sponsored by Gustave Roussy, To Explore the Role of the Gut Microbiome To Overcome ICI Resistance in Advanced NSCLC Patients with Antibiotic-Induced Dysbiosis"},"content":{"rendered":"\n<p><\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><strong>Lyon, France, January 20, 2026 \u2013 6:30pm CET \u2013 <a href=\"https:\/\/www.maatpharma.com\/\">MaaT Pharma<\/a> (EURONEXT: MAAT \u2013 the \u201cCompany\u201d), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, <\/strong>announced that the first patient has been randomized in the IMMUNOLIFE Phase 2 clinical trial, a randomized multicenter study evaluating the potential of an oral pooled fecal microbiotherapy (MaaT033) in combination with Regeneron\u2019s Cemiplimab (CB) in enhancing disease control rate versus best investigator\u2019s choice (BIC) in patients with advanced non-small cell lung cancer (NSCLC) who have developed resistance to PD-1\/PD-L1 blockade following antibiotic (ATB) exposure and who present ATB-induced gut dysbiosis.<\/p>\n\n\n\n<p><br><a href=\"https:\/\/www.maatpharma.com\/january-20-2026-maat-pharma-announces-first-patient-randomized-in-immunolife-phase-2-study-sponsored-by-gustave-roussy-to-explore-the-role-of-the-gut-microbiome-to-overcome-ici-resistance-in-advanc\/?_gl=1*usg8e8*_up*MQ..*_ga*MTc0MTc2MzEyOS4xNzY5NzY4NTUw*_ga_HYB4RS3WNS*czE3Njk3Njg1NDkkbzEkZzAkdDE3Njk3Njg1NDkkajYwJGwwJGgw\">To know more<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>MaaT Pharma Announces a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation<\/p>\n","protected":false},"author":6,"featured_media":37339,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[36,32,18],"tags":[],"class_list":["post-37337","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-our-members","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>MaaT Pharma Announces First Patient Randomized in IMMUNOLIFE Phase 2 Study Sponsored by Gustave Roussy, To Explore the Role of the Gut Microbiome To Overcome ICI Resistance in Advanced NSCLC Patients with Antibiotic-Induced Dysbiosis - MabDesign<\/title>\n<meta name=\"description\" content=\"MaaT Pharma Announces a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/mabdesign.fr\/en\/a-clinical-stage-biotechnology-company-and-a-leader-in-the-development-of-microbiome-ecosystem-therapiestm-met-dedicated-to-enhancing-survival-for-patients-with-cancer-through-immune-modulation\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MaaT Pharma Announces First Patient Randomized in IMMUNOLIFE Phase 2 Study Sponsored by Gustave Roussy, To Explore the Role of the Gut Microbiome To Overcome ICI Resistance in Advanced NSCLC Patients with Antibiotic-Induced Dysbiosis - MabDesign\" \/>\n<meta property=\"og:description\" content=\"MaaT Pharma Announces a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation\" \/>\n<meta property=\"og:url\" content=\"https:\/\/mabdesign.fr\/en\/a-clinical-stage-biotechnology-company-and-a-leader-in-the-development-of-microbiome-ecosystem-therapiestm-met-dedicated-to-enhancing-survival-for-patients-with-cancer-through-immune-modulation\/\" \/>\n<meta property=\"og:site_name\" content=\"MabDesign\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-30T11:01:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-30T11:04:32+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/01\/maat-logo-rvb-header.png\" \/>\n\t<meta property=\"og:image:width\" content=\"150\" \/>\n\t<meta property=\"og:image:height\" content=\"171\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Maissa Pote\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:site\" content=\"@MabDesign_fr\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Maissa Pote\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/mabdesign.fr\/en\/a-clinical-stage-biotechnology-company-and-a-leader-in-the-development-of-microbiome-ecosystem-therapiestm-met-dedicated-to-enhancing-survival-for-patients-with-cancer-through-immune-modulation\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/a-clinical-stage-biotechnology-company-and-a-leader-in-the-development-of-microbiome-ecosystem-therapiestm-met-dedicated-to-enhancing-survival-for-patients-with-cancer-through-immune-modulation\/\"},\"author\":{\"name\":\"Maissa Pote\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/dadad49556eefa9f367253af9f8e4029\"},\"headline\":\"MaaT Pharma Announces First Patient Randomized in IMMUNOLIFE Phase 2 Study Sponsored by Gustave Roussy, To Explore the Role of the Gut Microbiome To Overcome ICI Resistance in Advanced NSCLC Patients with Antibiotic-Induced Dysbiosis\",\"datePublished\":\"2026-01-30T11:01:24+00:00\",\"dateModified\":\"2026-01-30T11:04:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/a-clinical-stage-biotechnology-company-and-a-leader-in-the-development-of-microbiome-ecosystem-therapiestm-met-dedicated-to-enhancing-survival-for-patients-with-cancer-through-immune-modulation\/\"},\"wordCount\":146,\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/a-clinical-stage-biotechnology-company-and-a-leader-in-the-development-of-microbiome-ecosystem-therapiestm-met-dedicated-to-enhancing-survival-for-patients-with-cancer-through-immune-modulation\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/01\/maat-logo-rvb-header.png\",\"articleSection\":[\"News\",\"Our members\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/mabdesign.fr\/en\/a-clinical-stage-biotechnology-company-and-a-leader-in-the-development-of-microbiome-ecosystem-therapiestm-met-dedicated-to-enhancing-survival-for-patients-with-cancer-through-immune-modulation\/\",\"url\":\"https:\/\/mabdesign.fr\/en\/a-clinical-stage-biotechnology-company-and-a-leader-in-the-development-of-microbiome-ecosystem-therapiestm-met-dedicated-to-enhancing-survival-for-patients-with-cancer-through-immune-modulation\/\",\"name\":\"MaaT Pharma Announces First Patient Randomized in IMMUNOLIFE Phase 2 Study Sponsored by Gustave Roussy, To Explore the Role of the Gut Microbiome To Overcome ICI Resistance in Advanced NSCLC Patients with Antibiotic-Induced Dysbiosis - MabDesign\",\"isPartOf\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/a-clinical-stage-biotechnology-company-and-a-leader-in-the-development-of-microbiome-ecosystem-therapiestm-met-dedicated-to-enhancing-survival-for-patients-with-cancer-through-immune-modulation\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/a-clinical-stage-biotechnology-company-and-a-leader-in-the-development-of-microbiome-ecosystem-therapiestm-met-dedicated-to-enhancing-survival-for-patients-with-cancer-through-immune-modulation\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/01\/maat-logo-rvb-header.png\",\"datePublished\":\"2026-01-30T11:01:24+00:00\",\"dateModified\":\"2026-01-30T11:04:32+00:00\",\"description\":\"MaaT Pharma Announces a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation\",\"breadcrumb\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/a-clinical-stage-biotechnology-company-and-a-leader-in-the-development-of-microbiome-ecosystem-therapiestm-met-dedicated-to-enhancing-survival-for-patients-with-cancer-through-immune-modulation\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/mabdesign.fr\/en\/a-clinical-stage-biotechnology-company-and-a-leader-in-the-development-of-microbiome-ecosystem-therapiestm-met-dedicated-to-enhancing-survival-for-patients-with-cancer-through-immune-modulation\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/a-clinical-stage-biotechnology-company-and-a-leader-in-the-development-of-microbiome-ecosystem-therapiestm-met-dedicated-to-enhancing-survival-for-patients-with-cancer-through-immune-modulation\/#primaryimage\",\"url\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/01\/maat-logo-rvb-header.png\",\"contentUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/01\/maat-logo-rvb-header.png\",\"width\":150,\"height\":171},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/mabdesign.fr\/en\/a-clinical-stage-biotechnology-company-and-a-leader-in-the-development-of-microbiome-ecosystem-therapiestm-met-dedicated-to-enhancing-survival-for-patients-with-cancer-through-immune-modulation\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/mabdesign.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MaaT Pharma Announces First Patient Randomized in IMMUNOLIFE Phase 2 Study Sponsored by Gustave Roussy, To Explore the Role of the Gut Microbiome To Overcome ICI Resistance in Advanced NSCLC Patients with Antibiotic-Induced Dysbiosis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#website\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"name\":\"Mabdesign\",\"description\":\"The Biotherapy Expert\",\"publisher\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/mabdesign.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#organization\",\"name\":\"Mabdesign\",\"url\":\"https:\/\/mabdesign.fr\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"contentUrl\":\"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png\",\"width\":786,\"height\":233,\"caption\":\"Mabdesign\"},\"image\":{\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/MabDesign_fr\",\"https:\/\/www.linkedin.com\/company\/mabdesign\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/dadad49556eefa9f367253af9f8e4029\",\"name\":\"Maissa Pote\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/c0a02ac51ae23c4db179e2854e03e397b7afe326a9890c70d0f3b22cd90aac1d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/c0a02ac51ae23c4db179e2854e03e397b7afe326a9890c70d0f3b22cd90aac1d?s=96&d=mm&r=g\",\"caption\":\"Maissa Pote\"},\"url\":\"https:\/\/mabdesign.fr\/en\/author\/communication\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MaaT Pharma Announces First Patient Randomized in IMMUNOLIFE Phase 2 Study Sponsored by Gustave Roussy, To Explore the Role of the Gut Microbiome To Overcome ICI Resistance in Advanced NSCLC Patients with Antibiotic-Induced Dysbiosis - MabDesign","description":"MaaT Pharma Announces a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/mabdesign.fr\/en\/a-clinical-stage-biotechnology-company-and-a-leader-in-the-development-of-microbiome-ecosystem-therapiestm-met-dedicated-to-enhancing-survival-for-patients-with-cancer-through-immune-modulation\/","og_locale":"en_US","og_type":"article","og_title":"MaaT Pharma Announces First Patient Randomized in IMMUNOLIFE Phase 2 Study Sponsored by Gustave Roussy, To Explore the Role of the Gut Microbiome To Overcome ICI Resistance in Advanced NSCLC Patients with Antibiotic-Induced Dysbiosis - MabDesign","og_description":"MaaT Pharma Announces a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation","og_url":"https:\/\/mabdesign.fr\/en\/a-clinical-stage-biotechnology-company-and-a-leader-in-the-development-of-microbiome-ecosystem-therapiestm-met-dedicated-to-enhancing-survival-for-patients-with-cancer-through-immune-modulation\/","og_site_name":"MabDesign","article_published_time":"2026-01-30T11:01:24+00:00","article_modified_time":"2026-01-30T11:04:32+00:00","og_image":[{"width":150,"height":171,"url":"http:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/01\/maat-logo-rvb-header.png","type":"image\/png"}],"author":"Maissa Pote","twitter_card":"summary_large_image","twitter_creator":"@MabDesign_fr","twitter_site":"@MabDesign_fr","twitter_misc":{"Written by":"Maissa Pote","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/mabdesign.fr\/en\/a-clinical-stage-biotechnology-company-and-a-leader-in-the-development-of-microbiome-ecosystem-therapiestm-met-dedicated-to-enhancing-survival-for-patients-with-cancer-through-immune-modulation\/#article","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/a-clinical-stage-biotechnology-company-and-a-leader-in-the-development-of-microbiome-ecosystem-therapiestm-met-dedicated-to-enhancing-survival-for-patients-with-cancer-through-immune-modulation\/"},"author":{"name":"Maissa Pote","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/dadad49556eefa9f367253af9f8e4029"},"headline":"MaaT Pharma Announces First Patient Randomized in IMMUNOLIFE Phase 2 Study Sponsored by Gustave Roussy, To Explore the Role of the Gut Microbiome To Overcome ICI Resistance in Advanced NSCLC Patients with Antibiotic-Induced Dysbiosis","datePublished":"2026-01-30T11:01:24+00:00","dateModified":"2026-01-30T11:04:32+00:00","mainEntityOfPage":{"@id":"https:\/\/mabdesign.fr\/en\/a-clinical-stage-biotechnology-company-and-a-leader-in-the-development-of-microbiome-ecosystem-therapiestm-met-dedicated-to-enhancing-survival-for-patients-with-cancer-through-immune-modulation\/"},"wordCount":146,"publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/a-clinical-stage-biotechnology-company-and-a-leader-in-the-development-of-microbiome-ecosystem-therapiestm-met-dedicated-to-enhancing-survival-for-patients-with-cancer-through-immune-modulation\/#primaryimage"},"thumbnailUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/01\/maat-logo-rvb-header.png","articleSection":["News","Our members"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/mabdesign.fr\/en\/a-clinical-stage-biotechnology-company-and-a-leader-in-the-development-of-microbiome-ecosystem-therapiestm-met-dedicated-to-enhancing-survival-for-patients-with-cancer-through-immune-modulation\/","url":"https:\/\/mabdesign.fr\/en\/a-clinical-stage-biotechnology-company-and-a-leader-in-the-development-of-microbiome-ecosystem-therapiestm-met-dedicated-to-enhancing-survival-for-patients-with-cancer-through-immune-modulation\/","name":"MaaT Pharma Announces First Patient Randomized in IMMUNOLIFE Phase 2 Study Sponsored by Gustave Roussy, To Explore the Role of the Gut Microbiome To Overcome ICI Resistance in Advanced NSCLC Patients with Antibiotic-Induced Dysbiosis - MabDesign","isPartOf":{"@id":"https:\/\/mabdesign.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/mabdesign.fr\/en\/a-clinical-stage-biotechnology-company-and-a-leader-in-the-development-of-microbiome-ecosystem-therapiestm-met-dedicated-to-enhancing-survival-for-patients-with-cancer-through-immune-modulation\/#primaryimage"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/a-clinical-stage-biotechnology-company-and-a-leader-in-the-development-of-microbiome-ecosystem-therapiestm-met-dedicated-to-enhancing-survival-for-patients-with-cancer-through-immune-modulation\/#primaryimage"},"thumbnailUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/01\/maat-logo-rvb-header.png","datePublished":"2026-01-30T11:01:24+00:00","dateModified":"2026-01-30T11:04:32+00:00","description":"MaaT Pharma Announces a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune modulation","breadcrumb":{"@id":"https:\/\/mabdesign.fr\/en\/a-clinical-stage-biotechnology-company-and-a-leader-in-the-development-of-microbiome-ecosystem-therapiestm-met-dedicated-to-enhancing-survival-for-patients-with-cancer-through-immune-modulation\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/mabdesign.fr\/en\/a-clinical-stage-biotechnology-company-and-a-leader-in-the-development-of-microbiome-ecosystem-therapiestm-met-dedicated-to-enhancing-survival-for-patients-with-cancer-through-immune-modulation\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/a-clinical-stage-biotechnology-company-and-a-leader-in-the-development-of-microbiome-ecosystem-therapiestm-met-dedicated-to-enhancing-survival-for-patients-with-cancer-through-immune-modulation\/#primaryimage","url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/01\/maat-logo-rvb-header.png","contentUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2026\/01\/maat-logo-rvb-header.png","width":150,"height":171},{"@type":"BreadcrumbList","@id":"https:\/\/mabdesign.fr\/en\/a-clinical-stage-biotechnology-company-and-a-leader-in-the-development-of-microbiome-ecosystem-therapiestm-met-dedicated-to-enhancing-survival-for-patients-with-cancer-through-immune-modulation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/mabdesign.fr\/en\/"},{"@type":"ListItem","position":2,"name":"MaaT Pharma Announces First Patient Randomized in IMMUNOLIFE Phase 2 Study Sponsored by Gustave Roussy, To Explore the Role of the Gut Microbiome To Overcome ICI Resistance in Advanced NSCLC Patients with Antibiotic-Induced Dysbiosis"}]},{"@type":"WebSite","@id":"https:\/\/mabdesign.fr\/en\/#website","url":"https:\/\/mabdesign.fr\/en\/","name":"Mabdesign","description":"The Biotherapy Expert","publisher":{"@id":"https:\/\/mabdesign.fr\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/mabdesign.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/mabdesign.fr\/en\/#organization","name":"Mabdesign","url":"https:\/\/mabdesign.fr\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/","url":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","contentUrl":"https:\/\/mabdesign.fr\/wp-content\/uploads\/2022\/11\/logo-mabdesign.png","width":786,"height":233,"caption":"Mabdesign"},"image":{"@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/MabDesign_fr","https:\/\/www.linkedin.com\/company\/mabdesign\/"]},{"@type":"Person","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/dadad49556eefa9f367253af9f8e4029","name":"Maissa Pote","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mabdesign.fr\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/c0a02ac51ae23c4db179e2854e03e397b7afe326a9890c70d0f3b22cd90aac1d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/c0a02ac51ae23c4db179e2854e03e397b7afe326a9890c70d0f3b22cd90aac1d?s=96&d=mm&r=g","caption":"Maissa Pote"},"url":"https:\/\/mabdesign.fr\/en\/author\/communication\/"}]}},"_links":{"self":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/37337","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/comments?post=37337"}],"version-history":[{"count":2,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/37337\/revisions"}],"predecessor-version":[{"id":37347,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/posts\/37337\/revisions\/37347"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/media\/37339"}],"wp:attachment":[{"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/media?parent=37337"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/categories?post=37337"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mabdesign.fr\/en\/wp-json\/wp\/v2\/tags?post=37337"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}